Applications

1440 – PD-L1 testing for access to pembrolizumab in treatment naïve patients with locally advanced or metastatic non-small cell lung cancer

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome Not supported

Application details

Reason for application

New MBS item.

Service or technology in this application

ImmunoHistoChemistry test for evaluation of Programmed Cell Death Ligand 1 (PD-L1) expression to determine eligibility for treatment with pembrolizumab.

Type: Investigative

Medical condition this application addresses

Locally advanced or metastatic non-small cell lung cancer.

Application documents

Meetings to consider this application

  • PASC meeting: 11 - 12 August 2016
  • ESC meeting: 7 - 8 February 2017
  • MSAC meeting: 6 - 7 April 2017